Internal research tool, not commercially marked/cleared.
Clinical evidence
Vendor-supported
Not applicable (not commercially marketed).
Independent
Third-party industry report citing that the tool flagged 73% of pancreatic cancers at least 16 months before diagnosis — a research-stage finding, not yet a routine clinical deployment.
Real-world deployment
Research/validation stage at Mayo Clinic; not a generalizable commercial deployment.
Interoperability
European status
Editorial verdict
Limits and uncertainties
Still a research tool — do not present as ‘in production’ without clarifying this is investigational, internal use.
This profile is not medical advice or an endorsement. Hospitals should perform their own due diligence (regulatory compliance, GDPR, cybersecurity, integration, local clinical validation). How we evaluate
Every profile documents the precise indication, regulatory status, vendor-supported and independent evidence, real-world deployment, limits and dated sources.
A independent systematic review or prospective multicentre study · B at least one independent peer-reviewed study · C peer-reviewed, vendor-supported · D vendor claims only.